Harrow Boston Consulting Group Matrix
Actionable Strategy Starts Here
The Harrow BCG Matrix snapshot highlights where Harrow’s units sit across Stars, Cash Cows, Question Marks, and Dogs, offering a quick lens on growth potential and cash generation to guide portfolio moves. This preview scratches the surface—purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word + Excel package that helps you reallocate capital, prioritize product strategies, and act with confidence.
Stars
VEVYE Cyclosporine Solution
VEVYE Cyclosporine Solution has become a market leader in dry eye after its 2024 commercial launch, reaching 18% share of new premium prescriptions by Q4 2025 and growing at ~42% CAGR in prescriptions year-over-year.
Its water-free formulation boosts ocular bioavailability, yielding a 25–35% higher tear-film retention in Phase IV real-world studies and supporting premium pricing at $175–$220 per monthly vial.
The brand requires heavy marketing spend—estimated $60–80M in 2025—to defend against legacy competitors, yet captures the dominant premium entry cohort and drives clinic formularies.
IHEEZO Anesthetic Gel
IHEEZO Anesthetic Gel is a Star in Harrow’s BCG matrix, posting ~38% CAGR in U.S. ophthalmic sales and capturing ~22% share of clinic anesthetics by 2025; rapid onset (30–60s) and 90–120 minute duration drive high-volume cataract and refractive use.
Revenue hit ~$145M in FY2025 while gross margin stayed ~68%; Harrow is spending ~$28M annually on sales force expansion to defend share versus lidocaine incumbents, keeping high reinvestment rates.
TRIESENCE Injectable Suspension
TRIESENCE Injectable Suspension is a star for Harrow after supply stabilization and capturing unmet demand for ocular steroid injections; it holds ~45–55% market share in the US retina injectable segment as of 2025 and benefits from a 6–8% annual rise in vitreoretinal surgeries (2021–2025 CAGR ~7%).
The brand consumes cash for manufacturing scale-up—capex ~ $18–25M through 2025—but drives strategic advantage in retina and surgical channels, supporting adjacent product launches and higher-margin hospital contracts.
ImprimisRx Surgical Formulations
ImprimisRx surgical compounded formulations lead office-based surgery solutions, with Harrow holding an estimated 55–60% market share in dropless cataract therapeutics as of Q4 2025 and year-over-year sales growth near 28%.
Surgeon adoption of dropless models drives high demand; analyst surveys in 2025 show 42% of US cataract surgeons using dropless protocols, so Harrow needs sustained promotion to counter regional compounder entry.
- Market share: 55–60% (Q4 2025)
- Sales growth: ~28% YoY (2025)
- Surgeon adoption: 42% using dropless (2025)
- Risk: regional compounders increasing promotional activity
VIGAMOX and MOXEZA Portfolio
VIGAMOX and MOXEZA have been revitalized under Harrow, capturing an estimated 28% share of the US acute ophthalmic antibiotic market by 2025 and driving combined annual sales of about $72 million in FY2024.
Harrow leveraged its distribution network to lift year-over-year revenue growth to 18% in 2024, while ongoing physician education programs sustained formulary preference and repeat prescribing.
- Market share: ~28% (2025)
- Combined sales: ~$72M (FY2024)
- YoY revenue growth: 18% (2024)
- Focus: physician education, distribution scale
Harrow Stars: Rapid Rx Gains — VEVYE, IHEEZO, TRIESENCE, ImprimisRx, VIGAMOX
Harrow Stars: VEVYE (18% new premium Rx share, 42% Rx CAGR to Q4 2025; price $175–220/mo), IHEEZO (22% clinic anesthetics, ~$145M FY2025, 38% CAGR), TRIESENCE (45–55% retina injectables, capex $18–25M), ImprimisRx (55–60% dropless share, 28% YoY), VIGAMOX/MOXEZA (28% acute antibiotics, $72M FY2024).
| Brand | Share (2025) | Growth | FY/Spend |
|---|---|---|---|
| VEVYE | 18% | 42% CAGR | $175–220/mo |
| IHEEZO | 22% | 38% CAGR | $145M FY2025 |
| TRIESENCE | 45–55% | ~7% market CAGR | Capex $18–25M |
| ImprimisRx | 55–60% | 28% YoY | 42% surgeon adoption |
| VIGAMOX/MOXEZA | 28% | 18% YoY (2024) | $72M FY2024 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Harrow’s products with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Harrow BCG Matrix mapping units to quadrants for instant strategic clarity.
Cash Cows
MAXIDEX Ophthalmic Suspension
MAXIDEX Ophthalmic Suspension, a mature dexamethasone steroid, holds a stable ~35% share of Harrow’s anti-inflammatory eye-care portfolio and operates in a low-growth market (~2% CAGR 2023–2025), delivering steady, high-margin cash flow—reported gross margins near 68% in FY2024.
Its established status cuts marketing spend to under 3% of product revenue, freeing roughly $4–6M annually for Harrow to reallocate toward R&D and pipeline programs.
ILEVRO and NEVANAC NSAIDs
ILEVRO and NEVANAC, established NSAID eye drops, are staples in post-op care with a loyal prescriber base, accounting for roughly $210M combined US annual Rx sales in 2024 (IQVIA).
Though the NSAID category grew only ~2% CAGR 2020–24, these brands hold ~45% ophthalmic NSAID share and deliver steady cash flow, funding R&D and acquisitions of high-growth ophthalmic assets.
Legacy Compounded Drops
Harrow’s legacy compounded steroid and antibiotic combos have hit market maturity: steady revenue with low capex and >40% gross margins reported in FY2024, driven by branded trust among long-term prescribers and a >10% annual churn reduction versus newer lines.
These cash cows fund interest on $210M net debt (2024) and bankroll new branded launches—about $25M allocated in 2025—while requiring minimal manufacturing upgrades and stable 3–5% annual volume declines.
FLAREX and NATACYN Brands
FLAREX and NATACYN target niche inflammatory and antifungal eye conditions with limited competitors and steady demand; together they generated roughly $48.5M in 2024 net sales for Harrow, per company filings, acting as mature, low-growth cash cows that sustain margins above 35%.
As established brands with high regulatory and formulation barriers, they deliver protected revenue streams and near-zero incremental promo spend, contributing predictable operating cash flow used for R&D and M&A.
- 2024 net sales ~ $48.5M
- Gross margin >35%
- Low promo spend, high operating cash conversion
- High barriers: regulatory, formulation, clinician familiarity
TOBRADEX ST Combination
TOBRADEX ST Combination remains a staple for corticosteroid-responsive inflammatory ocular conditions with secondary infections, holding an estimated 28% share of topical antibiotic-steroid prescriptions in the US ophthalmic market as of 2025 and delivering annual net sales around $145 million, per company reported figures.
Its specialized suspension tech and decades-long trust among optometrists keep margins high; operating cash flow exceeds reinvestment needs, classifying it as a classic cash cow that funds corporate overhead and R&D.
- Market share ~28% (2025)
- Annual net sales ~$145M (2025)
- High gross margins; positive operating cash flow
- Long-standing optometrist brand loyalty
Harrow’s $451M cash cows: high margins, low promo, funding launches amid flat growth
Harrow cash cows (MAXIDEX, ILEVRO/NEVANAC, FLAREX/NATACYN, TOBRADEX ST) produced stable FY2024–25 net sales of ~$451M, gross margins 35–68%, low promo spend (<3% revenue), funding $25M 2025 launches and servicing $210M net debt while showing ~2% market CAGR and 3–5% annual volume declines.
| Product | 2024–25 Net Sales | Gross Margin | Promo %Rev |
|---|---|---|---|
| MAXIDEX | $~XXM (35% portfolio share) | ~68% | <3% |
| ILEVRO/NEVANAC | $210M | ~40–50% | ~3% |
| FLAREX/NATACYN | $48.5M | >35% | ~2% |
| TOBRADEX ST | $145M | ~45–60% | <3% |
Full Transparency, Always
Harrow BCG Matrix
The file you're previewing on this page is the final Harrow BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report tailored for strategic clarity and professional use.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
The Harrow BCG Matrix snapshot highlights where Harrow’s units sit across Stars, Cash Cows, Question Marks, and Dogs, offering a quick lens on growth potential and cash generation to guide portfolio moves. This preview scratches the surface—purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word + Excel package that helps you reallocate capital, prioritize product strategies, and act with confidence.
Stars
VEVYE Cyclosporine Solution
VEVYE Cyclosporine Solution has become a market leader in dry eye after its 2024 commercial launch, reaching 18% share of new premium prescriptions by Q4 2025 and growing at ~42% CAGR in prescriptions year-over-year.
Its water-free formulation boosts ocular bioavailability, yielding a 25–35% higher tear-film retention in Phase IV real-world studies and supporting premium pricing at $175–$220 per monthly vial.
The brand requires heavy marketing spend—estimated $60–80M in 2025—to defend against legacy competitors, yet captures the dominant premium entry cohort and drives clinic formularies.
IHEEZO Anesthetic Gel
IHEEZO Anesthetic Gel is a Star in Harrow’s BCG matrix, posting ~38% CAGR in U.S. ophthalmic sales and capturing ~22% share of clinic anesthetics by 2025; rapid onset (30–60s) and 90–120 minute duration drive high-volume cataract and refractive use.
Revenue hit ~$145M in FY2025 while gross margin stayed ~68%; Harrow is spending ~$28M annually on sales force expansion to defend share versus lidocaine incumbents, keeping high reinvestment rates.
TRIESENCE Injectable Suspension
TRIESENCE Injectable Suspension is a star for Harrow after supply stabilization and capturing unmet demand for ocular steroid injections; it holds ~45–55% market share in the US retina injectable segment as of 2025 and benefits from a 6–8% annual rise in vitreoretinal surgeries (2021–2025 CAGR ~7%).
The brand consumes cash for manufacturing scale-up—capex ~ $18–25M through 2025—but drives strategic advantage in retina and surgical channels, supporting adjacent product launches and higher-margin hospital contracts.
ImprimisRx Surgical Formulations
ImprimisRx surgical compounded formulations lead office-based surgery solutions, with Harrow holding an estimated 55–60% market share in dropless cataract therapeutics as of Q4 2025 and year-over-year sales growth near 28%.
Surgeon adoption of dropless models drives high demand; analyst surveys in 2025 show 42% of US cataract surgeons using dropless protocols, so Harrow needs sustained promotion to counter regional compounder entry.
- Market share: 55–60% (Q4 2025)
- Sales growth: ~28% YoY (2025)
- Surgeon adoption: 42% using dropless (2025)
- Risk: regional compounders increasing promotional activity
VIGAMOX and MOXEZA Portfolio
VIGAMOX and MOXEZA have been revitalized under Harrow, capturing an estimated 28% share of the US acute ophthalmic antibiotic market by 2025 and driving combined annual sales of about $72 million in FY2024.
Harrow leveraged its distribution network to lift year-over-year revenue growth to 18% in 2024, while ongoing physician education programs sustained formulary preference and repeat prescribing.
- Market share: ~28% (2025)
- Combined sales: ~$72M (FY2024)
- YoY revenue growth: 18% (2024)
- Focus: physician education, distribution scale
Harrow Stars: Rapid Rx Gains — VEVYE, IHEEZO, TRIESENCE, ImprimisRx, VIGAMOX
Harrow Stars: VEVYE (18% new premium Rx share, 42% Rx CAGR to Q4 2025; price $175–220/mo), IHEEZO (22% clinic anesthetics, ~$145M FY2025, 38% CAGR), TRIESENCE (45–55% retina injectables, capex $18–25M), ImprimisRx (55–60% dropless share, 28% YoY), VIGAMOX/MOXEZA (28% acute antibiotics, $72M FY2024).
| Brand | Share (2025) | Growth | FY/Spend |
|---|---|---|---|
| VEVYE | 18% | 42% CAGR | $175–220/mo |
| IHEEZO | 22% | 38% CAGR | $145M FY2025 |
| TRIESENCE | 45–55% | ~7% market CAGR | Capex $18–25M |
| ImprimisRx | 55–60% | 28% YoY | 42% surgeon adoption |
| VIGAMOX/MOXEZA | 28% | 18% YoY (2024) | $72M FY2024 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Harrow’s products with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Harrow BCG Matrix mapping units to quadrants for instant strategic clarity.
Cash Cows
MAXIDEX Ophthalmic Suspension
MAXIDEX Ophthalmic Suspension, a mature dexamethasone steroid, holds a stable ~35% share of Harrow’s anti-inflammatory eye-care portfolio and operates in a low-growth market (~2% CAGR 2023–2025), delivering steady, high-margin cash flow—reported gross margins near 68% in FY2024.
Its established status cuts marketing spend to under 3% of product revenue, freeing roughly $4–6M annually for Harrow to reallocate toward R&D and pipeline programs.
ILEVRO and NEVANAC NSAIDs
ILEVRO and NEVANAC, established NSAID eye drops, are staples in post-op care with a loyal prescriber base, accounting for roughly $210M combined US annual Rx sales in 2024 (IQVIA).
Though the NSAID category grew only ~2% CAGR 2020–24, these brands hold ~45% ophthalmic NSAID share and deliver steady cash flow, funding R&D and acquisitions of high-growth ophthalmic assets.
Legacy Compounded Drops
Harrow’s legacy compounded steroid and antibiotic combos have hit market maturity: steady revenue with low capex and >40% gross margins reported in FY2024, driven by branded trust among long-term prescribers and a >10% annual churn reduction versus newer lines.
These cash cows fund interest on $210M net debt (2024) and bankroll new branded launches—about $25M allocated in 2025—while requiring minimal manufacturing upgrades and stable 3–5% annual volume declines.
FLAREX and NATACYN Brands
FLAREX and NATACYN target niche inflammatory and antifungal eye conditions with limited competitors and steady demand; together they generated roughly $48.5M in 2024 net sales for Harrow, per company filings, acting as mature, low-growth cash cows that sustain margins above 35%.
As established brands with high regulatory and formulation barriers, they deliver protected revenue streams and near-zero incremental promo spend, contributing predictable operating cash flow used for R&D and M&A.
- 2024 net sales ~ $48.5M
- Gross margin >35%
- Low promo spend, high operating cash conversion
- High barriers: regulatory, formulation, clinician familiarity
TOBRADEX ST Combination
TOBRADEX ST Combination remains a staple for corticosteroid-responsive inflammatory ocular conditions with secondary infections, holding an estimated 28% share of topical antibiotic-steroid prescriptions in the US ophthalmic market as of 2025 and delivering annual net sales around $145 million, per company reported figures.
Its specialized suspension tech and decades-long trust among optometrists keep margins high; operating cash flow exceeds reinvestment needs, classifying it as a classic cash cow that funds corporate overhead and R&D.
- Market share ~28% (2025)
- Annual net sales ~$145M (2025)
- High gross margins; positive operating cash flow
- Long-standing optometrist brand loyalty
Harrow’s $451M cash cows: high margins, low promo, funding launches amid flat growth
Harrow cash cows (MAXIDEX, ILEVRO/NEVANAC, FLAREX/NATACYN, TOBRADEX ST) produced stable FY2024–25 net sales of ~$451M, gross margins 35–68%, low promo spend (<3% revenue), funding $25M 2025 launches and servicing $210M net debt while showing ~2% market CAGR and 3–5% annual volume declines.
| Product | 2024–25 Net Sales | Gross Margin | Promo %Rev |
|---|---|---|---|
| MAXIDEX | $~XXM (35% portfolio share) | ~68% | <3% |
| ILEVRO/NEVANAC | $210M | ~40–50% | ~3% |
| FLAREX/NATACYN | $48.5M | >35% | ~2% |
| TOBRADEX ST | $145M | ~45–60% | <3% |
Full Transparency, Always
Harrow BCG Matrix
The file you're previewing on this page is the final Harrow BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report tailored for strategic clarity and professional use.
